In-vitro Diagnostics Enzymes Market Size Worth $1.41 Billion By 2027

202年11月0 | Report Format: Electronic (PDF)

In-vitro Diagnostics Enzymes Market Growth & Trends

The globalin-vitro diagnostics enzymes marketsize is expected to reach USD 1.41 billion by 2027, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.97% from 2020 to 2027. Accurate and rapid diagnosis and treatment of clinical disorders are essential for optimal clinical outcomes. Owing to the noteworthy biocatalytic properties,enzymesare used in the diagnosis of a wide range of diseases.

The development of enzyme biosensors has increased the enzyme utility in clinical diagnostics. Despite the necessity in clinical diagnosis, the commercialization and translation of biosensors from research to clinics are still low. However, with an increase in R&D efforts, lactate, cholesterol, and glucose biosensors have been commercialized for diagnostic use.

Proteases are important signaling proteins that are critical to a few pathological processes, including cancer, neurological, inflammatory, and cardiovascular disorders. Polymerase and transcriptase enzymes are expected to exhibit the fastest CAGR over the forecast period. In addition, the presence of a substantial number of players that offer these enzymes is expected to enhance the growth. Key players such as Kaneka Eurogentec S.A.; Toyobo Co., Ltd.; and Sekisui Diagnostics, LLC manufacture and distribute a wide range of polymerases, including KOD DNA Polymerase, Taq DNA Polymerase, Tth DNA Polymerase, and TTx DNA Polymerase.

The infectious disease segment dominated the market in 2019. An exponential rise in the COVID-19 cases globally drives the adoption rate of diagnostic enzymes forCOVID-19 diagnosis. An increase in the availability of qualitative and quantitative molecular assays based on real-time PCR, Loop-mediated Isothermal Amplification- PCR (LAMP-PCR), multiplex PCR, and digital PCR technologies for the diagnosis of infectious diseases drives the demand for enzymes in this segment.

Enzymatic immunohistochemistry (IHC) is preferred for histology owing to a better contrast ratio and the method’s compatibility for use with multiple stains for the detection of target components. IVD enzymes are employed in different end-use settings for the analysis of tissue specimens and bodily fluids. A wide range of end users including large laboratories that conduct multiple analyses in a day and smaller clinics that conduct a few tests use enzymes forin-vitro diagnostics(IVD).

North America emerged as a prominent regional market in 2019. A rise in the number of cancer cases and the adoption of enzymes for histopathology of biopsy samples are some of the other factors expected to propel market growth in the region. The presence of a large target population, improvements in healthcare infrastructure, high unmet clinical needs, increase in government initiatives, and rise in R&D activities for advanced diagnostic techniques are anticipated to drive the Asia Pacific market with the fastest growth rate.

The key players in the market are involved in novel product launches, acquisitions, collaborations, partnerships, and geographical expansions to reinforce their market presence. For instance, in June 2020, Codexis, Inc. signed a collaboration agreement with Alphazyme LLC for the manufacture and co-marketing of high-fidelity DNA polymerase, T7 RNA polymerase, and reverse transcriptase.

---

Request a free sample copy or view report summary:In-vitro Diagnostics Enzymes Market Report

---

In-vitro Diagnostics Enzymes Market Report Highlights

• By enzyme type, polymerase and transcriptase enzymes held the largest share in 2019 owing to their wide applications in molecular diagnostic assays

• Based on disease type, the infectious disease segment is expected to dominate the market throughout the forecast period

• In terms of technology type, the histology assays segment held the largest share in 2019 owing to the utility of histology assays in cancer diagnostics, coupled with a rising incidence of different cancer types

• By end use, hospital and diagnostic labs dominated the market in 2019. They witness a high inflow of biopsy specimens for histopathology and cytopathology because of an increase in hospitalization and rise in the number of hospital admissions for cancer patients

• North America dominated the overall market in 2019 owing to the presence of a substantial number of players in this region including Innovative Research; Bio-Rad Laboratories, Inc.; Rockland Immunochemicals, Inc.; MyBioSource.com; and RayBiotech, Inc.

In-vitro DiagnosticsEnzymes Market Segmentation

Grand View Research has segmented the global in-vitro diagnostics enzymes market on the basis of enzyme type, disease type, technology type, end-use, and region:

IVD Enzymes Type Outlook (Revenue, USD Million, 2016 - 2027)

• Proteases

  • By Disease Type

    • Infectious disease

    • Diabetes

    • Oncology

    • Cardiology

    • Nephrology

    • Autoimmune diseases

    • Others

  • 技术的使用

    • Histology Assays

    • Molecular Diagnostics

    • PCR Assays

    • NGS Assays

    • Others

    • Clinical Chemistry

  • By Physical Form

    • Powder

    • Liquid

    • By Type

    • Natural

    • Recombinant

  • By End-use

    • Pharma & Biotech

    • Hospital & Diagnostic Labs

    • CROs

    • Academic Labs

• Polymerase & Transcriptase

• Ribonuclease

• Others

IVD Enzymes Disease Type Outlook (Revenue, USD Million, 2016 - 2027)

• Infectious disease

  • COVID-19 Testing

  • 他patitis

  • HIV

  • Others

• Diabetes

• Oncology

• Cardiology

• Nephrology

• Autoimmune diseases

• Others

IVD Enzymes Technology Type Outlook (Revenue, USD Million, 2016 - 2027)

• Histology Assays

• Molecular Diagnostics

  • PCR Assays

  • NGS Assays

  • Others

• Clinical Chemistry

IVD Enzymes End-use Outlook (Revenue, USD Million, 2016 - 2027)

• Pharma & Biotech

• Hospital & Diagnostic Labs

• Contract Research Organizations (CROs)

• Academic Labs

IVD Enzymes Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Spain

• Asia Pacific

  • Japan

  • China

  • India

• Latin America

  • Brazil

  • Mexico

• Middle East and Africa (MEA)

  • South Africa

List of Key Players of IVD Enzymes Market

• Merck KGaA

• Codexis, Inc.

• F. Hoffmann-La Roche Ltd.

• Amano Enzyme Inc.

• Advanced Enzymes Technologies Ltd.

• Biocatalysts Ltd.

• Amicogen

• Dyadic International

• BBI Solutions

• Affymetrix

• American Laboratories